Allysia Finley's Life Science column on A15 today — "Swalwell That Ends Well?" — uses the Swalwell moment as a hook to write a serious column on where the political economy leaves life sciences in 2026. For our healthcare exposure and for the new 10th theme proposal (Healthcare Innovation / Oncology), Finley is the most useful political-risk read in Monday's paper.
Finley's data:
- IRA drug-pricing negotiations are hitting the second wave. CMS selected 15 new drugs for 2027 Medicare pricing, and the large-cap pharma names on the list are already pricing it.
- FDA leadership is stable but cautious. The new FDA Commissioner is emphasizing post-market safety and accelerated approval scrutiny.
- Psychedelic and rare-disease pipelines are the bright spots. Trump's psychedelic EO accelerates MDMA, psilocybin, and ibogaine pathways.
Healthcare Sub-Theme Map
LLY, NVO, JNJ, ABBV
LLY remains the anchor. GLP-1 franchise + incretin-platform optionality.
RMED, BMY, AMGN
Revolution Medicines is the highest-asymmetry public-comp to the Viz.ai/AI-drug-discovery thesis.
RXRX, SDGR, RLAY
Recursion, Schrödinger, and Relay are the three public pure-plays that benefit from the same AI-reliability thesis Mims articulated in his Keywords column.
Book Alignment — Finley Healthcare Read
New 10th theme: Healthcare Innovation / Oncology at 4%. Five holdings: RMED, BMY, AMGN, LLY, RXRX. Finley's column is the pricing-risk map that makes this theme defensible.